We assume that optimal timing for the therapy would be the moment of the highest levels of the endogenous CD45–CD34 + CD271+ cells observed in the peripheral blood of stroke patients, which could reflect the increased release of the cells from bone marrow to peripheral blood in response to ischemic lesion mediators. Here, CD34 is linked to stroke disorder.